MedTrace Logo

Molecular Surveillance of Artemisinin Resistance Malaria in Myanmar

NCT02792816 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 550

Last updated 2016-06-08

No results posted yet for this study

Summary

Efficacy and safety of the artemisinin combination therapy (ACT) in uncomplicated falciparum malaria patients in Myanmar and artemisinin molecular markers analysis

Conditions

  • Drug Resistance
  • Plasmodium Falciparum Malaria

Interventions

DRUG

First line antimalarial in Myanmar (artemether-lumefrantrine, dihydroartemisinin-piperaquine, and artesunate-mefloquine)

Being a observational cohort study, one of the ACT was selected in each study site to assess the efficacy and safety.

Sponsors & Collaborators

  • Kangwon National University

    collaborator OTHER

  • Department of Medical Research, Lower Myanmar

    lead OTHER

Eligibility

Min Age
3 Months
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2013-12-31
Completion
2016-05-31

Countries

  • Burma

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02792816 on ClinicalTrials.gov